Synlogic, Inc

[Not Yet Scheduled]
Synlogic™ is pioneering the development of a novel class of living Synthetic Biotic™ medicines based on its proprietary drug discovery and development platform. Synlogic’s pipeline includes Synthetic Biotic medicines for the treatment of Phenylketonuria (PKU), Enteric hyperoxaluria, and solid tumors. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as inflammatory and immune disorders. For more information, please visit synlogictx.com.
Ticker:
SYBX
Exchange:
SYBX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
SYNB1934
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
Chief Business Officer
Synlogic